What exactly did Cowen do for the BTSG analyst rating on March 2, 2026?

Cowen & Co. maintained its **Buy** rating on **BTSG** and raised the price target to **$49** on March 2, 2026. The action is logged at 09:36 AM and was summarized by StreetInsider

How should investors interpret a maintained Buy with a raised price target for BTSG?

A maintained Buy with a higher price target signals that the analyst expects better future results but keeps the same risk/reward view. For **BTSG**, it suggests upside without a change in conviction

Does the Cowen note change Meyka AI’s grade for BTSG?

Cowen’s action supports Meyka AI’s current grade of **B+** for **BTSG**. The grade factors in benchmarks, sector performance, growth metrics, and analyst consensus

Where can I read the Cowen note and related company earnings information?

Cowen’s price target change was reported by StreetInsider [source](https://www.streetinsider.com/Analyst+Comments/BrightSpring+Health+%28BTSG%29+PT+Raised+to+%2449+at+TD+Cowen/26088476.html). For earnings details see the Q4 2025 call transcript on Seeking Alpha [source](https://seekingalpha.com/page

Analyst Ratings

Cowen Maintains Buy on BTSG BrightSpring Health Services, Inc. Common Stock Mar 2026

ByDanny Kontos March 3, 2026March 3, 2026

Cowen & Co. on March 2, 2026 maintained a Buy on BrightSpring Health Services, Inc. Common Stock (BTSG) and raised its price target to $49. The note, published at 09:36 AM, shows Cowen retains conviction in BrightSpring’s growth path while nudging expectations higher. In our Meyka AI coverage we flag that this single rating action is the only analyst change logged for BTSG on the date, and it comes shortly after the company’s Q4 2025 earnings call. The BTSG analyst rating action combines a maintained Buy with a clearer price target signal for investors